Strs Ohio Has $596,000 Stock Position in Cogent Biosciences, Inc. $COGT

Strs Ohio lifted its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) by 591.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,500 shares of the technology company’s stock after acquiring an additional 35,500 shares during the period. Strs Ohio’s holdings in Cogent Biosciences were worth $596,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Candriam S.C.A. acquired a new position in shares of Cogent Biosciences during the 2nd quarter worth approximately $3,068,000. Voya Investment Management LLC boosted its stake in shares of Cogent Biosciences by 110.0% in the third quarter. Voya Investment Management LLC now owns 61,623 shares of the technology company’s stock valued at $885,000 after buying an additional 32,279 shares during the period. Emerald Advisers LLC grew its position in Cogent Biosciences by 9.2% during the third quarter. Emerald Advisers LLC now owns 1,579,496 shares of the technology company’s stock worth $22,682,000 after buying an additional 133,722 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Cogent Biosciences during the 3rd quarter worth $885,000. Finally, Ensign Peak Advisors Inc raised its holdings in Cogent Biosciences by 162.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 49,325 shares of the technology company’s stock valued at $354,000 after acquiring an additional 30,500 shares in the last quarter.

Insider Activity at Cogent Biosciences

In other news, insider John Edward Robinson sold 90,000 shares of the stock in a transaction on Friday, December 26th. The stock was sold at an average price of $38.74, for a total value of $3,486,600.00. Following the completion of the transaction, the insider directly owned 140,002 shares in the company, valued at approximately $5,423,677.48. This represents a 39.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Fairmount Funds Management Llc sold 3,500,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $36.40, for a total value of $127,400,000.00. Following the sale, the director owned 5,503,418 shares in the company, valued at $200,324,415.20. This represents a 38.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,737,642 shares of company stock worth $136,600,345. Corporate insiders own 7.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on COGT shares. Robert W. Baird increased their target price on Cogent Biosciences from $14.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. upped their price objective on shares of Cogent Biosciences to $67.00 and gave the stock an “overweight” rating in a research report on Friday, December 19th. HC Wainwright raised their target price on shares of Cogent Biosciences to $52.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. UBS Group upgraded shares of Cogent Biosciences to a “strong-buy” rating in a research report on Wednesday, January 7th. Finally, Stifel Nicolaus upgraded shares of Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Monday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $39.55.

Cogent Biosciences Stock Down 1.9%

COGT stock opened at $37.65 on Friday. The stock has a market capitalization of $5.36 billion, a P/E ratio of -22.96 and a beta of 0.50. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23. Cogent Biosciences, Inc. has a 12 month low of $3.72 and a 12 month high of $43.73. The firm has a 50-day moving average price of $38.36 and a 200-day moving average price of $23.31.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings results on Monday, November 3rd. The technology company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04. As a group, equities research analysts anticipate that Cogent Biosciences, Inc. will post -2.42 EPS for the current fiscal year.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.